Literature DB >> 8945636

RXR-mediated regulation of the alpha-fetoprotein gene through an upstream element.

C Li1, J Locker, Y J Wan.   

Abstract

Retinoic acid (RA) is known to have potent effects on development and differentiation. RA exerts its effects on transcription through two distinct classes of nuclear receptors, the retinoic acid receptor (RAR) and the retinoid X receptor (RXR), that bind to specific RA-responsive elements (RARE) in target genes. alpha-Fetoprotein (AFP), a hepatocyte differentiation, maturation, and carcinogenesis marker, is transcriptionally upregulated by RA in McA-RH8994 hepatoma cells. Using deletion mapping analysis, we have identified a RARE-like sequence that is located between -2406 and -2378 of the transcription initiation site of the rat AFP gene. Sequence analysis demonstrated that this cis-acting element consists of three direct repeats and one inverted repeat of a GGGTCA-like half-site. The putative RARE can specifically bind to both RXR homodimers and RAR/RXR heterodimers as determined by gel mobility shift assays. A DR1 direct repeat was more efficient than a DR5 direct repeat oligonucleotide in competition for binding of the putative RARE to RXR and RAR/RXR. A mutagenesis study indicated that to have a full-strength induction, all the repeats were required. To further analyze the function of this element in vivo, a reporter gene construct of the putative RARE combined with the thymidine kinase promoter was cotransfected with RAR and RXR expression plasmids in CV1 cells. CAT assays demonstrated that overexpression of RXRalpha conferred the best RA response, consistent with our previous observation that 9-cis-RA is more potent than all-trans-RA for inducing the expression of the AFP gene. In addition, the RXR selective ligand LG100153 alone can stimulate the expression of the AFP gene. Our data suggest that an RXR-mediated pathway exists for modulation of AFP gene expression through a specific element.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8945636     DOI: 10.1089/dna.1996.15.955

Source DB:  PubMed          Journal:  DNA Cell Biol        ISSN: 1044-5498            Impact factor:   3.311


  4 in total

1.  Preclinical Evaluation of UAB30 in Pediatric Renal and Hepatic Malignancies.

Authors:  Alicia M Waters; Jerry E Stewart; Venkatram R Atigadda; Elizabeth Mroczek-Musulman; Donald D Muccio; Clinton J Grubbs; Elizabeth A Beierle
Journal:  Mol Cancer Ther       Date:  2016-02-12       Impact factor: 6.261

2.  Construction of a regulable gene therapy vector targeting for hepatocellular carcinoma.

Authors:  Shao-Ying Lu; Yan-Fang Sui; Zeng-Shan Li; Cheng-En Pan; Jing Ye; Wen-Yong Wang
Journal:  World J Gastroenterol       Date:  2003-04       Impact factor: 5.742

3.  Phase II trial of oral beta-all trans-retinoic acid in hepatocellular carcinoma (SWOG 9157).

Authors:  F L Meyskens; J Jacobson; B Nguyen; G R Weiss; D R Gandara; J S MacDonald
Journal:  Invest New Drugs       Date:  1998       Impact factor: 3.850

4.  Telomerase inhibition decreases alpha-fetoprotein expression and secretion by hepatocellular carcinoma cell lines: in vitro and in vivo study.

Authors:  Roula Tahtouh; Anne-Sophie Azzi; Nada Alaaeddine; Soulaima Chamat; Hasnaa Bouharoun-Tayoun; Layal Wardi; Issam Raad; Riad Sarkis; Najibe Abou Antoun; George Hilal
Journal:  PLoS One       Date:  2015-03-30       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.